|
PPS
Jul 20, 2016 14:53:54 GMT -5
Post by kball on Jul 20, 2016 14:53:54 GMT -5
I agree a 100% about scripts. Its frustrating to read so many posters who are just out of touch with the fact that MNKD is a drug company and they need to sell their product. They need to sell Afrezza. As investors we should not be concerned about RLS milestone (cause we dont even know anything about the company) SNY settlement or international partners.
They need to prove Afrezza can sell, anything else is just gravy at this point.
I agree, above all else, MannKind's future heavily depends on Afrezza. However, we should be concerned about milestone payments from RLS because MannKind is currently not making a profit, and the commercialization efforts for Afrezza cost money. If RLS ends up being ground-breaking and successful, then MannKind will gain more attention and recognition, which could greatly help in the commercialization of Afrezza. I think at this point RLS is the only thing that is outside of Mannkind that could potentially catapult MannKind into public awareness—if of course, their new drug(s) end up being as ground-breaking as Andrea Leone-Bay advertises them to be. Actually, even scripts are gravy at this point
|
|
|
Post by peppy on Jul 20, 2016 15:07:53 GMT -5
I agree, above all else, MannKind's future heavily depends on Afrezza. However, we should be concerned about milestone payments from RLS because MannKind is currently not making a profit, and the commercialization efforts for Afrezza cost money. If RLS ends up being ground-breaking and successful, then MannKind will gain more attention and recognition, which could greatly help in the commercialization of Afrezza. I think at this point RLS is the only thing that is outside of Mannkind that could potentially catapult MannKind into public awareness—if of course, their new drug(s) end up being as ground-breaking as Andrea Leone-Bay advertises them to be.Actually, even scripts are gravy at this point Mango, I am asking? does "their new drug(s) end up being as ground-breaking as Andrea Leone-Bay advertises them to be." (?)
What exactly are you saying? Am I missing something? What is your thinking?
|
|
|
Post by peppy on Jul 20, 2016 15:10:27 GMT -5
I agree, above all else, MannKind's future heavily depends on Afrezza. However, we should be concerned about milestone payments from RLS because MannKind is currently not making a profit, and the commercialization efforts for Afrezza cost money. If RLS ends up being ground-breaking and successful, then MannKind will gain more attention and recognition, which could greatly help in the commercialization of Afrezza. I think at this point RLS is the only thing that is outside of Mannkind that could potentially catapult MannKind into public awareness—if of course, their new drug(s) end up being as ground-breaking as Andrea Leone-Bay advertises them to be. Actually, even scripts are gravy at this point yes, we need scripts. Did Mike say 70% of scripts get approved?
In and Outsulin. afrezza. try it, you will like it.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 20, 2016 17:56:30 GMT -5
Actually, even scripts are gravy at this point Mango, I am asking? does "their new drug(s) end up being as ground-breaking as Andrea Leone-Bay advertises them to be." (?)
What exactly are you saying? Am I missing something? What is your thinking?
I was just referring to her LinkedIn profile: "Receptor Life Sciences, Inc. is a pharmaceutical development company based in Seattle, Washington. Receptor is quietly laying the foundation for groundbreaking new products in the specialty pharmaceutical market."
|
|
|
Post by brotherm1 on Jul 21, 2016 12:10:46 GMT -5
We've got ONE DOLLAR! $1 bid, now one-dollar 0001, will you give me one-dollar 0002? ONE DOLLAR 0002! Will you give me one-dollar 0003? Will you give me one-dollar 0003? We've got one-dollar 0002, now One-dollar 0001? Now 99 cents? Can I get one-dollar? One-dollar! We've got One-Dollar!..........
|
|
|
PPS
Jul 21, 2016 12:50:51 GMT -5
alethea likes this
Post by orlon on Jul 21, 2016 12:50:51 GMT -5
Ten years in development, one billion dollar cost, three attempts at approval before finally winning approval over two years ago, sabotaged by the partnership with Sanofi for a year, a one dollar stock being shorted big time (even among those who loan their shares out to shorts for a few shekels,) for a drug that makes a difference in people's lives. And almost all I read here is hope and what ifs. I agree with those who talk up scripts...if you have a great drug SELL the drug! Pure and simple. No sale of AFREZZA then bankruptcy. I think the current management team is doing their best to get it out in the market, but resources go only so far. Further dilution would probably make the PPS less a buck...might as well go bust at that point.
|
|
|
Post by myocat on Jul 25, 2016 9:05:54 GMT -5
MNKD 2nd QTR earning is scheduled on Aug 8. I hope we'll have more developing news on the relaunch. I spoke to a general practice doc this weekend about Afrezza and he said he has never heard of it. Hmmm.
|
|
|
Post by centralcoastinvestor on Jul 25, 2016 9:24:57 GMT -5
MNKD 2nd QTR earning is scheduled on Aug 8. I hope we'll have more developing news on the relaunch. I spoke to a general practice doc this weekend about Afrezza and he said he has never heard of it. Hmmm. I recently spoke to my general practice doctor as well and he had not heard of it either. It appears that most doctors and patients have not heard of Afrezza. Now one could lament the fact that after a year and a half, how could people not know about Afrezza? Or view this as a positive. It is well known that second launches of drugs are very difficult. I believe mainly due to the fact that many doctors and patients now have a negative view of whatever drug is being relaunched. That is not the case here. Sanofi did such a terrible job of marketing Afrezza that most everyone, except investors and early adopters, still do not know Afrezza even exists. That's good for MannKind because that gives Mike C. and team the chance for a positive first impression with most doctors and patients.
|
|
|
PPS
Jul 27, 2016 8:47:19 GMT -5
biffn likes this
Post by mbseeking on Jul 27, 2016 8:47:19 GMT -5
CCI I wish , really wish you are right. But I'm in a very dark place this past few days. . i want to believe , but the elephant in the room is the PBMs have this by the throat. And the other pharma have the PBMs by the you-know-whats. there is a very real chance that market rigidity is going to snuff a wonderful thing. Maybe this century that is where anti-trust should be focusing. Exactly how does someone who is not big pharma bring a new drug to market? I would have thought the absence of such a pathway is un-... American.
|
|
|
Post by biffn on Jul 27, 2016 13:14:37 GMT -5
Isn't it pretty obvious that the PPS is being manipulated to close under $1 every day? I hope MNKD is keeping an eye on this. Even if practically this has not effect, even after 30 days, you know the shorts are going to fill the headlines with delisting if it happens. There is no other reason for this. The fact that it can be manipulated to .9998 is just ridiculous.
|
|
|
Post by forlife on Jul 27, 2016 14:04:34 GMT -5
How closely is this being watched (or not) by the SEC? How much of this nonsense is criminal and how much is precision loop-hole knowledge?
|
|
|
Post by goyocafe on Jul 27, 2016 15:25:02 GMT -5
From Yahoo, shows MNKD closed at $1.00. Doesn't that restart the clock?
|
|
|
PPS
Jul 27, 2016 16:06:20 GMT -5
Post by biffn on Jul 27, 2016 16:06:20 GMT -5
From Yahoo, shows MNKD closed at $1.00. Doesn't that restart the clock? Yeah, I must have scared them.
|
|
|
PPS
Jul 27, 2016 18:16:37 GMT -5
Post by matt on Jul 27, 2016 18:16:37 GMT -5
From Yahoo, shows MNKD closed at $1.00. Doesn't that restart the clock? NASDAQ has tightened up the rules a bit. It needs to have a closing bid price of at least $1.00 for ten consecutive trading days to reset the clock. If the last trade was hitting a $1.00 ask but the bid was $0.99 then it doesn't count. Last trade may, or may not, have been on the bid.
|
|
|
Post by mbracket123 on Jul 27, 2016 22:24:18 GMT -5
Matt, thats not correct. The company must have a closing price below 1$ for 30 consecutive days to become deficient. If it becomes deficient, then a ten-day rule comes into effect:
Once a deficiency notice has been sent, the company has 90 days to comply with the continued listing standards, or 180 days if the violation was for a sub-$1.00 share price. In order to be compliant, the company's share price or market cap must rise above the minimum for at least 10 consecutive days in the 90-day (or 180-day) period.
So the clock does indeed reset every time the close is at least $1
Mike
|
|